← Back to Clinical Trials
Recruiting NCT03910569

The Cedars-Sinai Smidt Heart Institute Takotsubo Registry & Proteomic Study

Trial Parameters

Condition Takotsubo Cardiomyopathy
Sponsor Cedars-Sinai Medical Center
Study Type OBSERVATIONAL
Phase N/A
Enrollment 1,000
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2019-02-01
Completion 2029-02

Brief Summary

The Cedars-Sinai SHI Takotsubo Registry and Proteomic Study is an observational registry that will collect retrospective and prospective demographic, clinical, hemodynamic, laboratory and other diagnostic parameters, therapy and outcome data from individuals who meet the inclusion/exclusion criteria of Takotsubo Registry protocol. Subjects will also be invited to provide a blood sample utilizing a Mitra kit sent to their homes. Researchers from the Barbra Streisand Women's Heart Center will analyze Registry data to identify Takotsubo phenotypes, improve diagnostic capabilities, better predict recurrence rates, and develop targeted Takotsubo treatments.

Eligibility Criteria

Inclusion Criteria: * Have received a diagnosis of Takotsubo from their physician and consent to enroll * Submit full medical records needed for Takotsubo adjudication Exclusion Criteria: * Younger than 18 years * Unable to provide informed consent * Unable to provide the necessary documentation needed for screening purposes

Related Trials